INT178023

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 2004
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 11
Total Number 12
Disease Relevance 3.87
Pain Relevance 1.22

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Epo) extracellular region (Epo)
Anatomy Link Frequency
hippocampus 3
body 1
Epo (Mus musculus)
Pain Link Frequency Relevance Heat
Hippocampus 151 99.84 Very High Very High Very High
depression 122 99.16 Very High Very High Very High
long-term potentiation 98 89.20 High High
Pyramidal cell 28 81.40 Quite High
Inflammatory response 18 77.56 Quite High
cytokine 14 75.36 Quite High
imagery 7 57.52 Quite High
Inflammation 15 49.28 Quite Low
Glutamate 7 31.92 Quite Low
fibrosis 4 27.12 Quite Low
Disease Link Frequency Relevance Heat
Shock 17 100.00 Very High Very High Very High
Depression 120 99.16 Very High Very High Very High
Disease 88 99.12 Very High Very High Very High
Cognitive Disorder 191 99.08 Very High Very High Very High
Apoptosis 53 96.84 Very High Very High Very High
Critical Illness 12 93.80 High High
Sleep Disorders 2 92.12 High High
Body Weight 13 87.88 High High
Anxiety Disorder 56 86.16 High High
Neurodegenerative Disease 22 81.32 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We determined the effect of EPO treatment on short-term depression (STD) and LTD at Schaffer collateral CA1 pathway (Figure 3i–l).
Spec (determined) Regulation (effect) of EPO associated with depression
1) Confidence 0.45 Published 2008 Journal BMC Biol Section Body Doc Link PMC2562991 Disease Relevance 0.74 Pain Relevance 0.49
Neither volume of CA1 (control: 3.97 ± 0.11 mm3, N = 9; EPO: 4.02 ± 0.16 mm3, N = 10; P = 0.81) nor CA3 (control: 3.29 ± 0.21 mm3, N = 8; EPO: 3.56 ± 0.25 mm3, N = 10; P = 0.42), nor total hippocampal volume (control: 9.54 ± 0.34 mm3, N = 8, versus EPO: 9.74 ± 0.39 mm3, N = 10; P = 0.71) were significantly different.
Regulation (control) of EPO
2) Confidence 0.39 Published 2008 Journal BMC Biol Section Body Doc Link PMC2562991 Disease Relevance 0 Pain Relevance 0.13
Neither volume of CA1 (control: 3.97 ± 0.11 mm3, N = 9; EPO: 4.02 ± 0.16 mm3, N = 10; P = 0.81) nor CA3 (control: 3.29 ± 0.21 mm3, N = 8; EPO: 3.56 ± 0.25 mm3, N = 10; P = 0.42), nor total hippocampal volume (control: 9.54 ± 0.34 mm3, N = 8, versus EPO: 9.74 ± 0.39 mm3, N = 10; P = 0.71) were significantly different.
Regulation (control) of EPO
3) Confidence 0.39 Published 2008 Journal BMC Biol Section Body Doc Link PMC2562991 Disease Relevance 0.05 Pain Relevance 0.21
The gene expression of caspase 3 was not increased in ECM and was independent of rhEpo treatment, indicating that they are possibly not involved in the induction of apoptosis in ECM.
Neg (independent) Regulation (independent) of rhEpo associated with apoptosis
4) Confidence 0.38 Published 2008 Journal Malar J Section Body Doc Link PMC2257967 Disease Relevance 0.68 Pain Relevance 0.11
In search for a mechanism explaining the lasting influence of EPO on hippocampus-associated memory, we detected pronounced EPO effects on short-term and long-term plasticity, as well as on excitatory and inhibitory synaptic transmission in the Schaffer collateral CA1 pathway.
Regulation (influence) of EPO in hippocampus associated with hippocampus
5) Confidence 0.27 Published 2008 Journal BMC Biol Section Body Doc Link PMC2562991 Disease Relevance 0.23 Pain Relevance 0.08
One likely explanation for the selective improvement of contextual memory would be a direct influence of EPO on synaptic plasticity in the hippocampus.
Regulation (influence) of EPO in hippocampus associated with hippocampus
6) Confidence 0.27 Published 2008 Journal BMC Biol Section Body Doc Link PMC2562991 Disease Relevance 0.17 Pain Relevance 0.12
In search for a mechanism explaining the lasting influence of EPO on hippocampus-associated memory, we detected pronounced EPO effects on short-term and long-term plasticity, as well as on excitatory and inhibitory synaptic transmission in the Schaffer collateral CA1 pathway.
Regulation (effects) of EPO in hippocampus associated with hippocampus
7) Confidence 0.27 Published 2008 Journal BMC Biol Section Body Doc Link PMC2562991 Disease Relevance 0.22 Pain Relevance 0.08
EPO concentrations in the PBS- and EPO-treated grafts were not different from each other at each of the three time points (Table 1).


Regulation (concentrations) of EPO
8) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2981551 Disease Relevance 0.07 Pain Relevance 0
We believe this is not very surprising: as erythropoiesis is very sensitive to EPO levels, small changes in EPO levels may lead to very visible effects on hematocrit.
Regulation (changes) of EPO
9) Confidence 0.26 Published 2008 Journal Genet Vaccines Ther Section Body Doc Link PMC2276190 Disease Relevance 0.13 Pain Relevance 0
Year in review 2007: Critical Care – shock

The research papers on shock published in Critical Care throughout 2007 are related to three major subjects: the modulation of the macrocirculation and microcirculation during shock, focusing on arginine vasopressin, erythropoietin and nitric oxide; studies on metabolic homeostasis (acid–base status, energy expenditure and gastrointestinal motility); and basic supportive measures in critical illness (fluid resuscitation and sedation, and body-temperature management).

Regulation (modulation) of erythropoietin in body associated with critical illness, shock and sleep disorders
10) Confidence 0.26 Published 2008 Journal Crit Care Section Title Doc Link PMC2592773 Disease Relevance 0.48 Pain Relevance 0
EPO effects on basic behavior and cognition of young healthy mice after termination of EPO treatment were assessed.
Regulation (effects) of EPO associated with cognitive disorder
11) Confidence 0.24 Published 2008 Journal BMC Biol Section Body Doc Link PMC2562991 Disease Relevance 0.40 Pain Relevance 0
To summarize, the EPO analogue asialoEPO at the dosing protocol used here, is ineffective in the R6/2 model of HD.
Regulation (ineffective) of asialoEPO associated with disease
12) Confidence 0.23 Published 2004 Journal BMC Neurosci Section Body Doc Link PMC434499 Disease Relevance 0.69 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox